Piper Sandler on Sarepta Therapeutics (SRPT): 'SRPT Outperforms Revenue Guidance Driven By Elevidys'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.99 +0.45 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.54 | 52 Week High | $63.73 | |||
| Open | $18.94 | 52 Week Low | $8.00 | |||
| Day High | $19.28 | P/E | N/A | |||
| Day Low | $18.52 | EPS | $-5.69 | |||
| Volume | 1,328,151 | |||||
